Armistice Capital LLC Boosts Position in Inogen, Inc $INGN

Armistice Capital LLC boosted its position in Inogen, Inc (NASDAQ:INGN) by 46.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,264,000 shares of the medical technology company’s stock after purchasing an additional 400,000 shares during the period. Armistice Capital LLC’s holdings in Inogen were worth $8,494,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Trexquant Investment LP lifted its stake in shares of Inogen by 382.5% in the 4th quarter. Trexquant Investment LP now owns 74,129 shares of the medical technology company’s stock worth $498,000 after purchasing an additional 58,764 shares during the period. Jump Financial LLC purchased a new position in shares of Inogen in the fourth quarter worth approximately $200,000. Russell Investments Group Ltd. grew its position in Inogen by 14.6% during the fourth quarter. Russell Investments Group Ltd. now owns 19,543 shares of the medical technology company’s stock valued at $131,000 after buying an additional 2,487 shares during the period. Panagora Asset Management Inc. increased its holdings in Inogen by 48.4% during the fourth quarter. Panagora Asset Management Inc. now owns 48,195 shares of the medical technology company’s stock valued at $324,000 after buying an additional 15,715 shares during the last quarter. Finally, Barclays PLC raised its position in Inogen by 4.5% in the fourth quarter. Barclays PLC now owns 81,980 shares of the medical technology company’s stock worth $551,000 after acquiring an additional 3,515 shares during the period. 89.94% of the stock is currently owned by institutional investors.

Inogen Trading Down 0.6%

Inogen stock opened at $6.37 on Thursday. Inogen, Inc has a 12-month low of $5.34 and a 12-month high of $9.13. The firm has a market capitalization of $172.50 million, a price-to-earnings ratio of -7.00 and a beta of 1.60. The firm has a 50 day moving average of $6.61 and a 200 day moving average of $6.44.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). The firm had revenue of $85.11 million for the quarter, compared to analysts’ expectations of $82.35 million. Inogen had a negative net margin of 7.08% and a negative return on equity of 12.90%. On average, analysts predict that Inogen, Inc will post -0.77 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on INGN. Freedom Capital raised shares of Inogen to a “strong-buy” rating in a research report on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Inogen presently has a consensus rating of “Moderate Buy”.

Insider Buying and Selling at Inogen

In related news, EVP Boyer Jennifer M. Yi sold 10,770 shares of Inogen stock in a transaction on Friday, May 29th. The shares were sold at an average price of $6.53, for a total transaction of $70,328.10. Following the transaction, the executive vice president owned 15,977 shares in the company, valued at approximately $104,329.81. The trade was a 40.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.50% of the company’s stock.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.